Karijn P.M. Suijkerbuijk

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg et al. · New England Journal of Medicine · 2022 · 474 citations · Full text

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Irene L. M. Reijers, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · Nature Medicine · 2022 · 322 citations · Full text

Surgical Oncology, Oncology, Prado Trial +10

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis

James Larkin, Bartosz Chmielowski, Christopher D. Lao et al. · The Oncologist · 2017 · 257 citations · Full text

ESMO Guidance for Reporting Oncology real-World evidence (GROW)

Luís Castelo-Branco, Anna Pellat, Diogo Martins-Branco et al. · Annals of Oncology · 2023 · 183 citations · Full text

Medicine, Cancer Management, Cancer Registration +5